Director Dealing

RNS Number : 5504B

Destiny Pharma PLC

10 June 2021

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director Dealing

Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it was notified on 10 June 2021 that on that same day, Dr William Love, Chief Scientific Officer of the Company, sold 350,000 ordinary shares of 1 pence in the Company ("Ordinary Shares") at a price of 120 pence.

Following the sale, Dr William Love's beneficial interest in the Company is 6,509,500 Ordinary Shares, representing 10.87 per cent. of the total issued share capital.  Dr Love confirms that he does not intend to sell any further Ordinary Shares for the foreseeable future, that is until 2023 at the earliest.

Enquiries:

Destiny Pharma plc	[phone]
Neil Clark, CEO Shaun Claydon, CFO
finnCap Limited - Nominated Adviser and Joint Broker	[phone]
Geoff Nash / Kate Bannatyne (Corporate Finance) Alice Lane (ECM)
WG Partners LLP - Joint Broker	[phone]
Nigel Barnes / Claes Spång / Nigel Birks
Optimum Strategic Communications	[phone]
Mary Clark / Shabnam Bashir / Manel Mateus

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit  https://www.destinypharma.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr William Love
2.	Reason for the Notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/Amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1p each ("Ordinary Shares")
	Identification code	DEST  GB00BDHSP575
b)	Nature of the transaction	Sale of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) Sold 120 pence 350,000
d)	Aggregated information: · Aggregated volume · Price	See 4c) above
e)	Date of the transaction	10 June 2021
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END

 

 

DSHFLFEERLIILIL